Fialho Sílvia Ligório, Cunha Júnior Armando da Silva
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, MG, CEP 31270-010, Brazil.
Arq Bras Oftalmol. 2007 Jan-Feb;70(1):173-9. doi: 10.1590/s0004-27492007000100034.
The diseases of the posterior segment of the eye are responsible for most cases of irreversible blindness worldwide. These conditions stimulate the development of new modalities of treatment for vitreoretinal diseases. The success in the treatment aims, mainly, the delivery of effective doses of pharmacological agents directly to the target sites. Because of the difficulties in delivering drugs to the posterior segment of the eye, the development of intraocular delivery systems that allow the delivery of therapeutic concentrations of drugs for long periods are being studied. These systems offer many advantages, such as increase in drug bioavailability, obtaining constant and sustained drug release, to achievement of elevated local concentrations of drugs without systemic side effects, targeting one specific tissue or cell type, reducing the frequency of intraocular injections. These advantages can increase the comfort of the patient and reduce the complications observed with intraocular injections. Several drug delivery systems are being developed with the above described purposes. These systems may be prepared with biodegradable or non-biodegradable polymers or they may be lipid formulations. The drug delivery systems are represented, mainly, by micro- e nanoparticles and implants, composed of different polymers; by liposomes, which are made of lipids and surfactants; and by iontophoresis, that is based on the application of an electric current. In this review, the main characteristics of the different drug delivery systems will be shown, with their potentialities of clinical application.
眼后段疾病是全球大多数不可逆失明病例的病因。这些病症推动了玻璃体视网膜疾病新治疗方式的发展。治疗的成功主要目标是将有效剂量的药物直接递送至靶部位。由于将药物递送至眼后段存在困难,因此正在研究能够长时间递送治疗浓度药物的眼内递送系统。这些系统具有许多优点,例如提高药物生物利用度、实现药物持续稳定释放、在无全身副作用的情况下达到较高的局部药物浓度、靶向特定组织或细胞类型、减少眼内注射频率。这些优点可以提高患者的舒适度并减少眼内注射所观察到的并发症。为实现上述目的,正在开发几种药物递送系统。这些系统可以用可生物降解或不可生物降解的聚合物制备,也可以是脂质制剂。药物递送系统主要包括由不同聚合物组成的微球、纳米颗粒和植入物;由脂质和表面活性剂制成的脂质体;以及基于电流应用的离子电渗疗法。在本综述中,将展示不同药物递送系统的主要特性及其临床应用潜力。